Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target< (This gene does not contain this module)

Gene: KLF2

Summary for KLF2

Gene information	Gene symbol	KLF2
	Ensembl ID	ENSG00000127528
	Entrez ID	10365
	Gene name	KLF transcription factor 2
	Synonyms	LKLF
	Gene type	protein_coding
	UniProtAcc	Q9Y5W3

Top

Dataset with differentially expressed gene: KLF2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.344778	1.43e-15
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.818364	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.397286	4.97e-40
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.741006	3.97e-12
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.787093	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.864555	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.710396	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.646007	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.354666	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.777608	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.888671	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.812314	2.75e-09
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.34071	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.696786	1.75e-21
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	-0.446418	6.25e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.516568	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	-0.68807	3.28e-21
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.324704	1.76e-15
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.844268	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.363734	3.27e-05
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.458134	4.70e-11
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.729968	5.22e-31
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.944693	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.334467	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.585769	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	-0.86173	4.25e-10
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	-0.621777	1.01e-15
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-1.30393	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	-0.801423	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	-0.828441	8.31e-17
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.509006	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.753365	8.49e-23
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.35692	5.88e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	-0.297678	9.67e-11
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	0.992935	1.12e-12
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.8818	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.26966	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	-0.376898	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.588893	4.76e-32
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.575431	2.92e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-1.32822	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.544624	8.95e-05
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	-0.255738	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.614179	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.289417	1.27e-23
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.40098	3.49e-02
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.18637	2.79e-08
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	0.383526	5.99e-06
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	1.10919	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.351291	1.34e-40
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.284217	1.63e-04
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.38985	3.87e-06
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	1.15713	7.18e-38
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.302529	7.49e-15
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	0.393546	6.17e-04
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.58082	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	0.581559	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.400036	2.96e-37
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.526426	1.13e-26
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.464916	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	-0.528199	2.35e-06
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	0.506013	2.97e-11
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.851358	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD8+ T cells	0.745757	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	0.485911	1.83e-10
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	1.10788	1.08e-19
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	0.624295	7.02e-04
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	0.390667	1.40e-45
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.373357	9.11e-18
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.323011	6.10e-26
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.325011	3.46e-15

Top

Expression of KLF2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to KLF2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating KLF2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
KLF2	hsa-miR-4666a-3p	98.9776	NM_016270
KLF2	hsa-miR-16-2-3p	96.2375	NM_016270
KLF2	hsa-miR-195-3p	96.2375	NM_016270
KLF2	hsa-miR-767-5p	96.1941	NM_016270
KLF2	hsa-miR-101-3p	94.2939	NM_016270
KLF2	hsa-miR-338-5p	92.6228	NM_016270
KLF2	hsa-miR-4704-3p	88.4802	NM_016270
KLF2	hsa-miR-875-3p	86.7194	NM_016270
KLF2	hsa-miR-656-3p	85.3302	NM_016270
KLF2	hsa-miR-1299	83.9896	NM_016270
KLF2	hsa-miR-1910-5p	83.9682	NM_016270
KLF2	hsa-let-7a-3p	82.9545	NM_016270
KLF2	hsa-miR-98-3p	82.9545	NM_016270
KLF2	hsa-let-7f-1-3p	82.9545	NM_016270
KLF2	hsa-let-7b-3p	82.9545	NM_016270
KLF2	hsa-miR-323a-5p	82.704	NM_016270
KLF2	hsa-miR-3151-5p	82.3918	NM_016270
KLF2	hsa-miR-92a-3p	82.1854	NM_016270
KLF2	hsa-miR-32-5p	82.1854	NM_016270
KLF2	hsa-miR-92b-3p	82.1854	NM_016270
KLF2	hsa-miR-367-3p	80.6897	NM_016270
KLF2	hsa-miR-363-3p	80.6897	NM_016270
KLF2	hsa-miR-25-3p	80.6897	NM_016270
KLF2	hsa-miR-9902	80.6173	NM_016270

Page: 1

Top

Motifs and transcription factors (TFs) regulating KLF2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
KLF2	jaspar__MA1125.1	ZNF384 (directAnnotation).
KLF2	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
KLF2	kznf__ZNF613_Imbeault2017_RP_RCADE	ZNF613 (directAnnotation).
KLF2	cisbp__M01815	CEBPE (inferredBy_Orthology).
KLF2	taipale_tf_pairs__TEAD4_CLOCK_NCACGTGNNNNNNCATWCC_CAP_repr	CLOCK; TEAD4 (directAnnotation).
KLF2	transfac_pro__M04844	MAX (directAnnotation).
KLF2	homer__ATTGCGCAAC_CEBP	CEBPB (inferredBy_Orthology).
KLF2	taipale_tf_pairs__GCM1_FIGLA_CAGCTGNNNNNNNNTGCGGG_CAP	FIGLA; GCM1 (directAnnotation).
KLF2	kznf__ZNF250_Najafabadi2015_ChIP-seq	ZNF250 (directAnnotation).
KLF2	transfac_pro__M04761	HSF1 (directAnnotation).
KLF2	tfdimers__MD00336	IRF8; STAT1 (directAnnotation).
KLF2	metacluster_29.6	ZNF436 (directAnnotation).
KLF2	swissregulon__hs__CEBPB	CEBPB (directAnnotation).
KLF2	taipale_tf_pairs__FOXO1_HOXB13_GWMAACAYMRTAAA_CAP	FOXO1; HOXB13 (directAnnotation).
KLF2	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_repr	ZNF385D (directAnnotation).
KLF2	transfac_pro__M06401	ZNF551 (directAnnotation).
KLF2	transfac_pro__M06129	GLI4 (directAnnotation).
KLF2	taipale_tf_pairs__ELK1_FOXI1_RSCGGAANRWMAACAN_CAP_repr	ELK1; FOXI1 (directAnnotation).
KLF2	tfdimers__MD00187	GATA1; GATA2; GATA3; GATA4; GATA5; GATA6 (directAnnotation).
KLF2	metacluster_46.5	HLF; TEF (directAnnotation).
KLF2	metacluster_71.2	EPAS1 (directAnnotation).
KLF2	transfac_pro__M06162	ZNF93 (directAnnotation).
KLF2	tfdimers__MD00547	FOXM1; TFAP2A (directAnnotation).
KLF2	swissregulon__hs__FUBP1	FUBP1 (directAnnotation).
KLF2	transfac_pro__M04855	IRF4 (directAnnotation).
KLF2	transfac_pro__M05544	BCL11A (directAnnotation).
KLF2	taipale_tf_pairs__HOXB2_ETV7_NSCGGAARNNNNNNMATTAN_CAP_repr	ETV7; HOXB2 (directAnnotation).
KLF2	taipale_tf_pairs__GCM1_ETV7_NTNNNGGCGGAAGNNNTTCCNNN_CAP_repr	ETV7; GCM1 (directAnnotation).
KLF2	transfac_pro__M06086	ZNF17 (directAnnotation).
KLF2	transfac_pro__M05930	ZNF286A (directAnnotation).
KLF2	metacluster_56.5	HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology).
KLF2	metacluster_46.4	CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; DBP; DBP; EP300; GATAD2A; HES2 (directAnnotation). CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; HLF; HLF (inferredBy_Orthology).
KLF2	metacluster_26.4	CDC5L; CDC5L; CDC5L; ZNF580; ZNF580 (directAnnotation).
KLF2	transfac_pro__M05701	ZNF30 (directAnnotation).
KLF2	metacluster_21.5	HOXB2; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4 (directAnnotation). HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF1; HSF2; HSF2; HSF2; HSF2; HSF4; HSF4; HSF4; HSF4; HSF5; HSF5; HSF5; HSF5; HSFX1; HSFX1; HSFX1; HSFX1; HSFX2; HSFX2; HSFX2; HSFX2; HSFX3; HSFX3; HSFX3; HSFX3; HSFX4; HSFX4; HSFX4; HSFX4; HSFY1; HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2; HSFY2 (inferredBy_Orthology).
KLF2	metacluster_90.10	ZNF135 (directAnnotation).
KLF2	hocomoco__CPEB1_HUMAN.H11MO.0.D	CPEB1 (directAnnotation).
KLF2	metacluster_130.9	ZNF569 (directAnnotation). ZNF569 (inferredBy_Orthology).
KLF2	taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP	ATF4; TEF (directAnnotation).
KLF2	tfdimers__MD00281	CDX2; HNF4A; HNF4G; NR2F1; NR2F2 (directAnnotation).
KLF2	transfac_pro__M06072	ZNF623 (directAnnotation).
KLF2	transfac_pro__M06232	ZNF234 (directAnnotation).
KLF2	metacluster_27.20	ZNF708; ZNF787; ZNF787; ZNF85 (directAnnotation).
KLF2	transfac_pro__M01251	E2F1 (directAnnotation).
KLF2	nitta__sens_TATGCT40NACT_KAA_AATAAATCACTGCA_m1_c3	GFI1 (inferredBy_Orthology).
KLF2	transfac_pro__M06270	ZNF468 (directAnnotation).
KLF2	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
KLF2	transfac_pro__M06818	ZNF592 (inferredBy_Orthology).
KLF2	taipale_tf_pairs__FOXJ2_HOXB13_TTTWATNRNMAACA_CAP_repr	FOXJ2; HOXB13 (directAnnotation).
KLF2	tfdimers__MD00007	E2F1; IRF8 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
KLF2	metacluster_195.2	up	Malignant cells	GSE152469	NA
KLF2	metacluster_3.10	down	Malignant cells	GSE153697	NA
KLF2	metacluster_163.1	down	Malignant cells	GSE153697	NA
KLF2	metacluster_163.1	up	Malignant cells	GSE161801_IMiD	pre
KLF2	transfac_pro__M07461	up	Malignant cells	GSE163836	NA
KLF2	transfac_pro__M08819	up	Malignant cells	GSE163836	NA
KLF2	metacluster_170.2	down	B cells	GSE169246_PacAteTissue	post
KLF2	metacluster_163.1	down	B cells	GSE169246_PacAteTissue	post
KLF2	transfac_pro__M07461	down	B cells	GSE169246_PacAteTissue	post
KLF2	metacluster_195.2	down	B cells	GSE169246_PacAteTissue	post
KLF2	metacluster_3.10	down	B cells	GSE169246_PacAteTissue	post
KLF2	metacluster_3.10	up	B cells	GSE169246_PacTissue	pre
KLF2	metacluster_195.2	up	B cells	GSE169246_PacTissue	pre
KLF2	metacluster_170.2	up	Malignant cells	GSE189460	pre
KLF2	metacluster_195.2	up	Malignant cells	GSE189460	pre
KLF2	metacluster_163.1	down	Malignant cells	GSE199333	pre
KLF2	metacluster_3.10	down	Malignant cells	GSE199333	pre
KLF2	metacluster_170.2	down	Malignant cells	GSE199333	pre
KLF2	metacluster_195.2	down	Malignant cells	GSE199333	pre
KLF2	metacluster_163.1	up	B cells	GSE207422_Sin	post
KLF2	metacluster_170.2	up	B cells	GSE207422_Sin	post
KLF2	metacluster_170.2	down	CD4+ T cells	PMID34715028	post

Page: 1

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."